The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma

Abstract Fibroblast growth factor receptor (FGFR)−2 can be inhibited by FGFR-selective or non-selective tyrosine kinase inhibitors (TKIs). Selective TKIs are approved for cholangiocarcinoma (CCA) with FGFR2 fusions; however, their application is limited by a characteristic pattern of adverse events...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Stephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko, Aaron Stahl, Yvonne Rasen, Christine Geisler, Kristina Ruhm, Marion Klaumuenzer, Thales Kronenberger, Stefan A. Laufer, Holly Sundberg-Malek, Khac Cuong Bui, Marius Horger, Saskia Biskup, Klaus Schulze-Osthoff, Markus Templin, Nisar P. Malek, Antti Poso, Michael Bitzer
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Nature Portfolio 2024-02-01
סדרה:	Nature Communications
גישה מקוונת:	https://doi.org/10.1038/s41467-024-45247-6
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!